Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
Hansa Medical, a Swedish biopharmaceutical company focusing on novel immunomodulatory enzymes, has appointed Henk Doude van Troostwijk as Vice President, Commercial Operations.
Molecular Devices®, market leader in microplate reader technology for over 25 years, has announced the launch of its SpectraMax® i3 Multi-Mode Detection Platform with SpectraMax® MiniMax® Imaging Cytometer.
Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimers disease. The news follows a recently announced R&D collaboration with Biogen.
The Oligo PRO 96XT system provides fast, automated and economical size-based purity analysis of single stranded DNA and RNA oligonucleotides, and double stranded RNA interference (RNAi) products.
Belgian CRO and service provider Genea has appointed a new Chief Medical Officer. Jörn Balzer will be responsible for the clinical, safety and risk management in Genaes research services.
Diabetes vaccine developer Diamyd Medical has a new CEO. From now on, Ulf Hannelius will lead the Stockholm-based company.
Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
The GeneArt® CRISPR Nuclease mRNA is wild type Cas9 as mRNA, for genome editing using CRISPR-Cas9 technology.